関連する実験動画

Updated: Feb 18, 2026

Assessment of the Metabolic Profile of Primary Leukemia Cells
06:21

Assessment of the Metabolic Profile of Primary Leukemia Cells

Published on: November 21, 2018

11.0K

急性リンパ性白血病の小児における治療に関連する肝毒性に関連した脂質学的プロファイル

Emily J Mason1,2, Jeremy M Schraw1,2, John P Woodhouse1,2

  • 1Baylor College of Medicine, One Baylor Plaza, BCM 622, Houston, TX, 77030, USA.

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
|February 16, 2026
PubMed
まとめ

幼児白血病の治療は肝臓に害を与える可能性があります. この研究では,高レベルのフォスファディチルコリン (PC) とスフィンゴミエリン (SM) を含む特定の脂質プロファイルが,急性リンパ性白血病 (ALL) の小児における肝損傷に関連していることが判明しました.

キーワード:
急性リンパ性白血病 (Acute Lymphoblastic Leukemia) とは,急性リンパ性白血病 (Acute Lymphoblastic Leukemia) とは,急性リンパ性白血病 (Acute Lymphoblastic Leukemia) とは,急性リンパ性白血病 (Acute Lymphoblastic Leukemia) とは,急性リンパ性白血病 (Acute Lymphoblastic Leukemia) とは,急性リンパ性白血病 (Acute Lymphoblastic Leukemia) とは,急性リンパ性白血病 (Acute Lymphoblastic Leukemia) とは,急性リンパ性白血病 (Acute Lymphoblastic Leukemia) とは,急性リンパ性白血病 (Acute Lymphoblasticリピドミカルプロファイリング治療に関連した肝毒性.

さらに関連する動画

Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia08:31

Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia

Published on: October 17, 2025

730
Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model06:08

Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model

Published on: February 10, 2023

1.9K

関連する概念動画

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
212
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
337
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
257
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
284